WAVE PHARMA LIMITED - Accounts to registrar (filleted)

REGISTERED NUMBER: 08350673 (England and Wales)

Unaudited Financial Statements

For The Year Ended 31 January 2026

for

WAVE PHARMA LIMITED

Page

Company Information

1

Balance Sheet

2

Notes to the Financial Statements

4

DIRECTORS:

M A Khan

Mrs R Khan

SECRETARY:

Mrs R Khan

REGISTERED OFFICE:

79 College Road

Harrow

Middlesex

HA1 1BD

REGISTERED NUMBER:

08350673 (England and Wales)

ACCOUNTANTS:

Ayman Tyler Associates

Accountants & Tax Advisers

79 College Road

Harrow

Middlesex

HA1 1BD

FIXED ASSETS

Tangible assets

4

3,359

514

Investments

5

300,000

303,359

300,514

CURRENT ASSETS

Stocks

41,305

41,642

Debtors

6

1,335,077

1,741,304

Cash at bank and in hand

56,084

78,506

1,432,466

1,861,452

CREDITORS

Amounts falling due within one year

7

1,414,345

1,908,354

NET CURRENT ASSETS/(LIABILITIES)

18,121

(46,902

)

TOTAL ASSETS LESS CURRENT
LIABILITIES

321,480

253,612

CAPITAL AND RESERVES

Called up share capital

8

100

Retained earnings

321,380

253,512

SHAREHOLDERS' FUNDS

321,480

253,612

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 January 2026.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 January 2026 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

(a)	ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b)

preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 12 March 2026 and were signed on its behalf by:

M A Khan - Director

1.	STATUTORY INFORMATION

WAVE PHARMA LIMITED is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2.	ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover

Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Plant and machinery etc

-

33% on cost

Investments in associates

Investments in associate undertakings are recognised at cost.

Stocks

Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation

Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Hire purchase and leasing commitments

Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits

The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3.	EMPLOYEES AND DIRECTORS

The average number of employees during the year was 6 (2025 - 5 ) .

4.	TANGIBLE FIXED ASSETS

Plant and

machinery

etc

£

COST

At 1 February 2025

9,699

Additions

4,234

At 31 January 2026

13,933

DEPRECIATION

At 1 February 2025

9,185

Charge for year

1,389

At 31 January 2026

10,574

NET BOOK VALUE

At 31 January 2026

3,359

At 31 January 2025

514

5.	FIXED ASSET INVESTMENTS

Interest

in

associate

£

COST

At 1 February 2025

and 31 January 2026

300,000

NET BOOK VALUE

At 31 January 2026

300,000

At 31 January 2025

300,000

The company's investments at the Balance Sheet date in the share capital of companies include the following:

Associated companies

On 6th January 2025, the company acquired 4 Ordinary shares in Eiman Pharma Limited representing a 2% holding for £300,000.. The principal activity of Eiman Pharma Limited is that of pharmaceutical quality control testing & research.

6.

DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

31.1.26

31.1.25

£

Trade debtors

666,829

1,453,930

Other debtors

668,248

287,374

1,335,077

1,741,304

Other Debtors balance includes £67,778 to H S Juttla, £14,365 to Arise Pharma Ltd, £229,055 to Ria Generics Ltd & £6,000 to Naveen Kumar Sunka.

7.

CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

31.1.26

31.1.25

£

Trade creditors

288,778

1,153,504

Taxation and social security

63,140

194,598

Other creditors

1,062,427

560,252

1,414,345

1,908,354

Other Creditors balance includes £92,575 loaned by ASA Life PTE, £79,825 by Asia Brothers Group, £218,363 by Baggia Trading PTE, £53,008 by Digital Impex PTE & £499,500 by Eiman Pharma Ltd.

8.	CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:

Number:

Class:

Nominal

31.1.26

31.1.25

value:

£

100

Ordinary

£1

100

The shareholdings in the company are as follows;

Mohammad Arsalaan Khan 50 Ordinary Shares of £1 each

Romana Khan 50 Ordinary Shares of £1 each

9.	OTHER FINANCIAL COMMITMENTS

The company entered into a 5 year lease agreement commencing 8th October 2024 for the ground floor premises at, Cavendish House 369-391 Burnt Oak, Edgware, Middlesex, HA8 5AW at an annual rental of £25,837.50 with rent review on the 1st January 2026.